2,4-二氯-6-硝基苯胺 | 2683-43-4

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4-二氯-6-硝基苯胺
• 英文名称: 2,4-dichloro-6-nitroaniline
• 英文别名: 2,4-dichloro-6-nitro phenylamine
• CAS: 2683-43-4
• 化学式: C₆H₄Cl₂N₂O₂
• mdl: MFCD00007664
• 分子量: 207.016
• InChiKey: IZEZAMILKKYOPW-UHFFFAOYSA-N

物化性质

• 熔点：
  101-103 °C (lit.)
• 沸点：
  360.98°C (rough estimate)
• 密度：
  1.6257 (rough estimate)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xn
• 安全说明：
  S26,S37/39
• 危险类别码：
  R20/21/22,R36/37/38,R33,R22,R26/27/28,R51/53
• WGK Germany：
  3
• 危险品运输编号：
  UN 2811 6.1/PG 3
• 海关编码：
  2921420090
• 危险类别：
  6.1
• 包装等级：
  III
• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P330,P362+P364,P403+P233,P501
• 危险性描述：
  H315,H319,H335,H302+H312+H332

SDS

Name:	2 4-Dichloro-6-nitroaniline 99% Material Safety Data Sheet
Synonym:	Non
CAS:	2683-43-4

Section 1 - Chemical Product MSDS Name:2 4-Dichloro-6-nitroaniline 99% Material Safety Data Sheet
Synonym:Non

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2683-43-4	2,4-Dichloro-6-nitroaniline, 99%	99%	220-241-7

Hazard Symbols: XN
Risk Phrases: 22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. May cause methemoglobinemia, cyanosis (bluish discoloration of skin due to deficient oxygenation of the blood), convulsions, and death. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. May cause effects similar to those described for ingestion.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid contact with skin and eyes. Avoid ingestion and inhalation. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits CAS# 2683-43-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 101 - 103 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H4Cl2N2O2
Molecular Weight: 207.02

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Has not been fully evaluated.
Conditions to Avoid:
None reported.
Incompatibilities with Other Materials:
Acids, acid chlorides, acid anhydrides, chloroformates, strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2683-43-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,4-Dichloro-6-nitroaniline, 99% - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
Safety Phrases:
WGK (Water Danger/Protection)
CAS# 2683-43-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2683-43-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2683-43-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,4-二氯-6-硝基苯胺 在 亚硝酸异戊酯 作用下， 生成 3,5-二氯硝基苯
  参考文献：
  名称：

  Berti,G. et al., Gazzetta Chimica Italiana, 1977, vol. 107, p. 175 - 180

  摘要：

  DOI：
• 作为产物：
  描述：

  2-硝基苯胺 在 N-chloro-N-(benzenesulfonyl)benzenesulfonamide 作用下， 以 乙腈 为溶剂， 反应 0.17h， 以98.8%的产率得到2,4-二氯-6-硝基苯胺
  参考文献：
  名称：

  N-氯-N-（苯磺酰基）苯磺酰胺（NCBSI）对活化的芳烃进行无活化剂的快速，环保的氯化反应

  摘要：

  N-氯-N-（苯磺酰基）苯磺酰胺（NCBSI）首次被开发为无需任何活化剂即可直接氯化各种活化的芳烃和杂环的氯化试剂。的比较中，计算机芯片上进行研究，以确定NCBSI亲电性质和市售Ñ氯试剂，以揭示理论的角度来看的反应性。通过避免使用有害的次氯酸叔丁基酯的改进方法制备了该试剂。与其他N-氯试剂相比，该试剂具有很高的反应活性。试剂N的前体从废废水中回收-（苯磺酰基）苯磺酰胺，可将其再循环以合成NCBSI。环保协议同样适用于工业上重要的氯氧亚麻酚作为抗菌剂的合成。

  DOI：

  10.1016/j.tetlet.2020.152689

文献信息

• [EN] ALLOSTERIC PROTEIN KINASE MODULATORS<br/>[FR] MODULATEURS DE PROTÉINE KINASE ALLOSTÉRIQUE
  申请人：UNIV SAARLAND

  公开号：WO2010043711A1

  公开（公告）日：2010-04-22

  The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

  该发明提供特定的小分子化合物，这些化合物能够变构调节AGC蛋白激酶的活性或调节Aurora家族蛋白激酶的蛋白-蛋白相互作用，提供这些化合物的制备方法，包含这些化合物的药物组合物，以及它们用于制备治疗和预防与AGC蛋白激酶或Aurora家族蛋白激酶异常活动相关疾病的药物的应用。
• ALLOSTERIC PROTEIN KINASE MODULATORS
  申请人：Engel Matthias

  公开号：US20120046307A1

  公开（公告）日：2012-02-23

  The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

  本发明提供了特定的小分子化合物，它们通过变构调节AGC蛋白激酶的活性或调节Aurora家族蛋白激酶的蛋白质-蛋白质相互作用，其生产方法，包含该化合物的药物组合物，以及它们用于制备治疗和预防与AGC蛋白激酶或Aurora家族蛋白激酶异常活动相关疾病的药物的应用。
• Glycine receptor antagonists and the use thereof
  申请人：The State of Oregon, acting by and through The Oregon State Board of

  公开号：US05514680A1

  公开（公告）日：1996-05-07

  Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.

  治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元损失的方法，以及治疗包括阿尔茨海默病、肌萎缩侧索硬化、亨廷顿病和唐氏综合症在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度活跃的副作用，以及治疗焦虑、慢性疼痛、癫痫、诱导麻醉和治疗精神病的方法，通过向需要此类治疗的动物施用一种对甘氨酸结合位点具有高亲和力、无PCP副作用且能穿过动物血脑屏障的化合物来进行披露。还披露了新型的1,4-二氢喹诺酮-2,3-二酮，及其药物组合物。还披露了1,4-二氢喹诺酮-2,3-二酮的高度可溶性铵盐。
• Chemical uncouplers for the treatment of obesity
  申请人：——

  公开号：US20040138301A1

  公开（公告）日：2004-07-15

  This invention relates to chemical uncouplers with a broader safety window making the use of them in treating obesity and, consequently, in the treatment of obesity related diseases and conditions such as atherosclerosis, hypertension, diabetes, especially type 2 diabetes (NIDDM (non-insulin dependent diabetes mellitus)), impaired glucose tolerance, dyslipidemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of cancer such as endometrial, breast, prostate and colon cancers and the risk for premature death as well as other conditions, such as diseases and disorders, which conditions are improved by an increase in mitochondrial respiration, more attractive.

  这项发明涉及一种化学解偶联剂，它具有更宽的安全窗口，使其在治疗肥胖症以及因此引发的相关疾病和状况，如动脉硬化、高血压、糖尿病（尤其是2型糖尿病（非胰岛素依赖型糖尿病））、葡萄糖耐量受损、血脂异常、冠心病、胆结石病、骨关节炎以及子宫内膜、乳房、前列腺和结肠等各种癌症以及过早死亡的风险等方面更具吸引力。此外，还包括其他通过增加线粒体呼吸得到改善的条件、疾病和紊乱。
• 作为神经保护剂的药用化合物
  申请人：江苏先声药业有限公司

  公开号：CN104045552B

  公开（公告）日：2019-06-11

  本发明公开了一类作为神经保护剂的药用化合物，其为神经元型一氧化氮合酶‑突触后密度蛋白‑95（nNOS‑PSD95）的解耦联剂，其为具有通式（Ⅰ）苯环衍生物或其药学上可接受的盐。本申请进一步公开了该类化合物的制备方法以及其用于预防和治疗受神经元损伤影响引起的疾病的用途。

表征谱图